Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.

Trial Profile

Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Tenofovir alafenamide (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 10 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 01 Dec 2017 Planned End Date changed from 31 Dec 2018 to 31 Aug 2019.
    • 01 Dec 2017 Planned primary completion date changed from 31 Dec 2018 to 31 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top